Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Selective Targeting of a Disease-Related Conformational Isoform of Macrophage Migration Inhibitory Factor Ameliorates Inflammatory Conditions.
Thiele M, Kerschbaumer RJ, Tam FW, Völkel D, Douillard P, Schinagl A, Kühnel H, Smith J, McDaid JP, Bhangal G, Yu MC, Pusey CD, Cook HT, Kovarik J, Magelky E, Bhan A, Rieger M, Mudde GC, Ehrlich H, Jilma B, Tilg H, Moschen A, Terhorst C, Scheiflinger F. Thiele M, et al. Among authors: schinagl a. J Immunol. 2015 Sep 1;195(5):2343-52. doi: 10.4049/jimmunol.1500572. Epub 2015 Jul 24. J Immunol. 2015. PMID: 26209628 Free PMC article.
Pharmacokinetics, disease-modifying activity, and safety of an experimental therapeutic targeting an immunological isoform of macrophage migration inhibitory factor, in rat glomerulonephritis.
Höllriegl W, Bauer A, Baumgartner B, Dietrich B, Douillard P, Kerschbaumer RJ, Höbarth G, McKee JS, Schinagl A, Tam FWK, Thiele M, Weber A, Wolfsegger M, Turecek M, Muchitsch EM, Scheiflinger F, Glantschnig H. Höllriegl W, et al. Among authors: schinagl a. Eur J Pharmacol. 2018 Feb 5;820:206-216. doi: 10.1016/j.ejphar.2017.12.040. Epub 2017 Dec 20. Eur J Pharmacol. 2018. PMID: 29274331 Free article.
The newly engineered monoclonal antibody ON104, targeting the oxidized Macrophage Migration Inhibitory Factor (oxMIF), ameliorates clinical and histopathological signs of collagen-induced arthritis.
Ferhat M, Mangano K, Mirkina I, Mayer J, Rossmueller G, Schinagl A, Kerschbaumer R, Nicoletti F, Thiele M, Landlinger C. Ferhat M, et al. Among authors: schinagl a. Eur J Pharmacol. 2023 Oct 5;956:175997. doi: 10.1016/j.ejphar.2023.175997. Epub 2023 Aug 12. Eur J Pharmacol. 2023. PMID: 37579967 Free article.
13 results